Predictive value of soluble urokinase plasminogen activator receptor, soluble ST2, and IL-33 in bronchopulmonary dysplasia

Pediatric Research

Volumn 75, Issue 6, 2014, Pages 788-792

  Tunc, Turan ^a   Cekmez, Ferhat ^a   Yildirim, Sukran ^b   Bulut, Ozgul ^b   Ince, Zeynep ^b   Saldir, Mehmet ^a   Aydemir, Gokhan ^c   Yaman, Halil ^a   Coban, Asuman ^b  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

^c GATA HAYDARPASA TRAINING HOSPITAL   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BETAMETHASONE; INTERLEUKIN 33; PROTEIN; SOLUBLE ST2 PROTEIN; SOLUBLE UROKINASE RECEPTOR; UNCLASSIFIED DRUG; UROKINASE RECEPTOR; BIOLOGICAL MARKER; CELL SURFACE RECEPTOR; IL1RL1 PROTEIN, HUMAN; IL33 PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE;

AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DELIVERY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INFANT; LUNG DYSPLASIA; MALE; NEWBORN INTENSIVE CARE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; RISK FACTOR; UMBILICAL CORD; BLOOD; BRONCHOPULMONARY DYSPLASIA; NEWBORN; PREMATURITY; SENSITIVITY AND SPECIFICITY;

BIOLOGICAL MARKERS; BRONCHOPULMONARY DYSPLASIA; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; INTERLEUKINS; PROSPECTIVE STUDIES; RECEPTORS, CELL SURFACE; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 84900838300     PISSN: 00313998     EISSN: 15300447     Source Type: Journal    
DOI: 10.1038/pr.2014.28     Document Type: Article

References (30)

1. Kinsella JP, Greenough A, Abman SH. Bronchopulmonary dysplasia. Lancet 2006;367:1421-31.
2. Ambalavanan N, Carlo WA. Ventilatory strategies in the prevention and management of bronchopulmonary dysplasia. Semin Perinatol 2006;30:192-9.
3. Kul M, Saldir M, Gulgun M, Kesik V, Sarici SU, Alpay F. Retrospective evaluation of low birth weight newborns followed up with the diagnosis of respiratory distress syndrome in the newborn intensive care unit. Gulhane Med J 2005;47:290-3.
4. Bhandari V, Finer NN, Ehrenkranz RA, et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Synchronized nasal intermittent positive-pressure ventilation and neonatal outcomes. Pediatrics 2009;124:517-26.
5. Ehrenkranz RA, Das A, Wrage LA, et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Early nutrition mediates the infuence of severity of illness on extremely LBW infants. Pediatr Res 2011;69:522-9.
6. Sarici SU, Kul M, Candemir G, Gursel O, Alpay F, Gokcay E. Inhaled nitric oxide in a preterm newborn with severe hypoxemic respiratory failure. Gulhane Med J 2004;46:255-7.
7. Reyburn B, Martin RJ, Prakash YS, MacFarlane PM. Mechanisms of injury to the preterm lung and airway: implications for long-term pulmonary outcome. Neonatology 2012;101:345-52.
8. Aghai ZH, Saslow JG, Mody K, et al. IFN-γ and IP-10 in tracheal aspirates from premature infants: relationship with bronchopulmonary dysplasia. Pediatr Pulmonol 2013;48:8-13.
9. Wright CJ, Kirpalani H. Targeting infammation to prevent bronchopul-monary dysplasia: can new insights be translated into therapies? Pediatrics 2011;128:111-26.
10. Oshikawa K, Yanagisawa K, Tominaga Si, Sugiyama Y. ST2 protein induced by infammatory stimuli can modulate acute lung infammation. Biochem Biophys Res Commun 2002;299:18-24.
11. Xu D, Jiang HR, Kewin P, et al. IL-33 exacerbates antigen-induced arthritis by activating mast cells. Proc Natl Acad Sci U S A 2008;105:10913-8.
12. Sanada S, Hakuno D, Higgins LJ, Schreiter ER, McKenzie AN, Lee RT. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotec-tive signaling system. J Clin Invest 2007;117:1538-49.
13. Alves-Filho JC, Sônego F, Souto FO, et al. Interleukin-33 attenuates sepsis by enhancing neutrophil infux to the site of infection. Nat Med 2010;16:708-12.
14. May AE, Schmidt R, Kanse SM, et al. Urokinase receptor surface expression regulates monocyte adhesion in acute myocardial infarction. Blood 2002;100:3611-7.
15. Fazioli F, Resnati M, Sidenius N, Higashimoto Y, Appella E, Blasi F. A uro-kinase-sensitive region of the human urokinase receptor is responsible for its chemotactic activity. EMBO J 1997;16:7279-86.
16. Fernebro E, Madsen RR, Fernö M, et al. Prognostic importance of the soluble plasminogen activator receptor, suPAR, in plasma from rectal cancer patients. Eur J Cancer 2001;37:486-91.
17. Eugen-Olsen J, Andersen O, Linneberg A, et al. Circulating soluble uro-kinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population. J Intern Med 2010;268:296-308.
18. Sehestedt T, Lyngbæk S, Eugen-Olsen J, et al. Soluble urokinase plasmino-gen activator receptor is associated with subclinical organ damage and cardiovascular events. Atherosclerosis 2011;216:237-43.
19. Schrama AJ, Bernard A, Poorthuis BJ, Zwinderman AH, Berger HM, Walther FJ. Cord blood Clara cell protein CC16 predicts the development of bronchopulmonary dysplasia. Eur J Pediatr 2008;167:1305-12.
20. Stolarski B, Kurowska-Stolarska M, Kewin P, Xu D, Liew FY. IL-33 exacerbates eosinophil-mediated airway infammation. J Immunol 2010;185:3472-80.
21. Martinez-Rumayor A, Camargo CA, Green SM, Baggish AL, O'Donoghue M, Januzzi JL. Soluble ST2 plasma concentrations predict 1-year mortality in acutely dyspneic emergency department patients with pulmonary disease. Am J Clin Pathol 2008;130:578-84.
22. Eugen-Olsen J, Gustafson P, Sidenius N, et al. The serum level of soluble urokinase receptor is elevated in tuberculosis patients and predicts mortality during treatment: a community study from Guinea-Bissau. Int J Tuberc Lung Dis 2002;6:686-92.
23. Kofoed K, Eugen-Olsen J, Petersen J, Larsen K, Andersen O. Predicting mortality in patients with systemic infammatory response syndrome: an evaluation of two prognostic models, two soluble receptors, and a macrophage migration inhibitory factor. Eur J Clin Microbiol Infect Dis 2008;27:375-83.
24. Koch A, Voigt S, Kruschinski C, et al. Circulating soluble urokinase plas-minogen activator receptor is stably elevated during the frst week of treatment in the intensive care unit and predicts mortality in critically ill patients. Crit Care 2011;15:R63.
25. Sarafdis K, Drossou-Agakidou V, Kanakoudi-Tsakalidou F, et al. Evidence of early systemic activation and transendothelial migration of neutrophils in neonates with severe respiratory distress syndrome. Pediatr Pulmonol 2001;31:214-9.
26. van Zoelen MA, Florquin S, de Beer R, et al. Urokinase plasminogen activator receptor-defcient mice demonstrate reduced hyperoxia-induced lung injury. Am J Pathol 2009;174:2182-9.
27. Shushakova N, Eden G, Dangers M, et al. The urokinase/urokinase receptor system mediates the IgG immune complex-induced infammation in lung. J Immunol 2005;175:4060-8.
28. Vik T, Vatten L, Markestad T, Jacobsen G, Bakketeig LS. Dubowitz assessment of gestational age and agreement with prenatal methods. Am J Peri-natol 1997;14:369-73.
29. Ehrenkranz RA, Walsh MC, Vohr BR, et al; National Institutes of Child Health and Human Development Neonatal Research Network. Validation of the National Institutes of Health consensus defnition of bronchopulmo-nary dysplasia. Pediatrics 2005;116:1353-60.
30. Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med 2001;163:1723-9.